```html

Zollinger‑Ellison Syndrome (ZES): A Complete Patient Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder characterized by one or more gastrin‑producing tumors (gastrinomas) that lead to excessive gastric acid secretion. The high‑acid environment causes recurrent peptic ulcers, gastro‑esophageal reflux disease (GERD), and a range of gastrointestinal (GI) symptoms.

Who it affects: ZES can occur at any age but most commonly presents in adults between 30 and 60 years. Both men and women are affected, though studies suggest a slight male predominance (≈55 %).

Prevalence: The syndrome is estimated to affect about 1–3 individuals per million worldwide. Approximately 20–30 % of patients have multiple endocrine neoplasia type 1 (MEN‑1), an inherited condition that predisposes to gastrinomas and other endocrine tumors.<sup>1</sup>

Symptoms

Symptoms arise from both the hyperacidic stomach environment and, when the tumor spreads, from mass effect or hormone production. The following list is comprehensive; many patients experience only a subset.

Gastro‑intestinal symptoms

• Recurrent peptic ulcers – often multiple, located beyond the duodenum (e.g., jejunal ulcers) and resistant to standard ulcer therapy.
• Abdominal pain – dull, gnawing pain that may improve after eating (due to ulcer healing) or worsen with ulcer perforation.
• Diarrhea – chronic, watery stools caused by rapid gastric emptying and bile‑acid malabsorption.
• Steatorrhea (fatty stools) – occurs when excess acid inactivates pancreatic enzymes.
• Nausea & vomiting – especially after large meals.
• Gastro‑esophageal reflux disease (GERD) – heartburn, regurgitation, and potential esophagitis.

Systemic symptoms

• Weight loss – due to malabsorption, chronic diarrhea, and reduced appetite.
• Fatigue – secondary to anemia (from chronic blood loss) or nutrient deficiencies.
• Metallic taste – some patients report a sour or metallic mouthfeel.

Signs of metastatic disease (≈25 % of cases)

• Abdominal mass or fullness.
• Upper‑right quadrant pain (if liver metastases develop).
• Elevated fasting gastrin levels (>1,000 pg/mL) with a gastric pH <2.

Causes and Risk Factors

ZES results from gastrin‑producing neuroendocrine tumors (NETs) that arise in the pancreas, duodenum, or, rarely, within gastric tissue.

Primary causes

• Sporadic gastrinomas – 70–80 % of cases; tumors develop without a known inherited disorder.
• Multiple endocrine neoplasia type 1 (MEN‑1) – a genetic syndrome caused by mutations in the MEN1 tumor suppressor gene. About 20–30 % of ZES patients have MEN‑1, and they tend to develop multiple small duodenal gastrinomas.

Risk factors

• Family history of MEN‑1 or other endocrine neoplasias.
• Known MEN1 gene mutation carriers.
• Previous diagnosis of a pancreatic or duodenal neuroendocrine tumor.
• Smoking – may increase the risk of neuroendocrine tumor development (relative risk ~1.4).<sup>2</sup>

Diagnosis

Diagnosing ZES requires a combination of clinical suspicion, biochemical testing, and imaging to locate the gastrinoma.

Biochemical tests

• Fasting serum gastrin level – a level >100 pg/mL is abnormal; >1,000 pg/mL strongly suggests ZES, especially when gastric pH <2.
• Secretin stimulation test – paradoxical rise in gastrin after IV secretin administration (≥120 pg/mL rise) confirms gastrinoma in equivocal cases.
• Gastric pH measurement – confirms hyperacidity (pH ≤2) which helps differentiate ZES from other hypergastrinemic states.

Imaging studies

• Endoscopic ultrasound (EUS) – high sensitivity (≈85 %) for detecting small pancreatic or duodenal lesions.
• Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT – preferred for staging and identifying metastatic disease.
• CT or MRI abdomen – useful for evaluating size, local invasion, and liver metastases.
• Upper endoscopy (EGD) – visualizes ulcer burden and obtains biopsies to rule out Helicobacter pylori infection.

Additional work‑up

• Genetic testing for MEN1 mutations when there is a family history or multiple endocrine tumors.
• Baseline labs: CBC, CMP, fasting lipid panel, and vitamin levels (especially fat‑soluble vitamins A, D, E, K).

Treatment Options

Therapeutic goals are to control acid hypersecretion, remove or control the gastrinoma, and manage complications.

Acid‑suppression therapy (first line)

• High‑dose Proton Pump Inhibitors (PPIs) – e.g., omeprazole 60 mg daily or equivalent. PPIs are 90–95 % effective at ulcer healing and symptom control.<sup>3</sup>
• In refractory cases, potassium‑competitive acid blockers (PCABs) such as vonoprazan may be used (off‑label in the U.S.).

Definitive tumor management

1. Surgical resection – the only curative option for localized gastrinomas.
   • Pancreaticoduodenectomy (Whipple) for head‑of‑pancreas lesions.
   • Limited enucleation for small duodenal tumors.
   • In MEN‑1 patients, surgery is more selective because of multifocal disease; debulking may improve symptoms.
2. Medical therapy for unresectable or metastatic disease
   • Somatostatin analogues (octreotide or lanreotide) – reduce gastrin secretion and may stabilize tumor growth.
   • Targeted therapy – everolimus or sunitinib (approved for progressive pancreatic NETs).
   • Chemotherapy – streptozocin‑based regimens for high‑grade disease, though response rates are modest.
3. Peptide receptor radionuclide therapy (PRRT) – 177Lu‑DOTATATE for patients with strong somatostatin receptor expression; improves progression‑free survival in NETs.
4. Liver‑directed therapies for hepatic metastases: radiofrequency ablation, transarterial embolization, or surgical resection when feasible.

Lifestyle and supportive measures

• Small, frequent meals to reduce gastric emptying stress.
• Avoidance of NSAIDs, aspirin, and alcohol – all aggravate ulcer formation.
• Calcium and vitamin D supplementation if malabsorption is present.
• Regular monitoring of bone density, as chronic acid hypersecretion can impair calcium absorption.

Living with Zollinger‑Ellison Syndrome

Daily management tips

• Medication adherence – take PPIs at the same time each day, preferably 30 minutes before a meal.
• Monitor symptoms – keep a diary of ulcer pain, frequency of diarrhea, and any new abdominal fullness.
• Nutrition – prioritize low‑fat, high‑protein foods; incorporate soluble fiber (e.g., oatmeal) to mitigate diarrhea.
• Hydration – replace fluids lost through diarrhea; oral rehydration solutions are helpful.
• Regular follow‑up – endocrinology/ gastroenterology visits every 3–6 months initially, then annually if stable.
• Screen for MEN‑1 manifestations – periodic calcium, prolactin, and parathyroid hormone checks.

Psychosocial considerations

Chronic illness can cause anxiety and depression. Access to a support group (e.g., NET Patient Foundation) and counseling services is advisable. Discuss fertility and pregnancy plans with a specialist; most PPIs are considered safe, but tumor‑directed therapies may need adjustment.

Prevention

Because most ZES cases are sporadic, primary prevention is limited. However, risk reduction strategies include:

• Genetic counseling and testing for individuals with a family history of MEN‑1.
• Smoking cessation – reduces overall NET risk.
• Early evaluation of persistent or recurrent ulcers, especially if they are atypical (e.g., beyond the duodenum) or unresponsive to standard therapy.
• Eradication of Helicobacter pylori and avoidance of chronic NSAID use to minimize confounding ulcer causes.

Complications

If left untreated or inadequately controlled, ZES can lead to serious health problems:

• Perforated ulcer – life‑threatening abdominal emergency.
• Bleeding ulcer – may cause anemia or require transfusion.
• Gastro‑intestinal obstruction – from strictures or tumor bulk.
• Malabsorption syndromes – chronic diarrhea, nutrient deficiencies, and osteoporosis.
• Metastatic disease – liver, lymph nodes, or rarely, lungs and bones; associated with reduced survival (5‑year survival ≈60 % for metastatic ZES versus >90 % for localized disease).<sup>4</sup>
• MEN‑1 related tumors – hyperparathyroidism, pituitary adenomas, and other pancreatic NETs.

When to Seek Emergency Care

---

Sources:

1. Mayo Clinic – Zollinger‑Ellison syndrome
2. CDC – Neuroendocrine Tumors
3. Cleveland Clinic – ZES
4. Journal of Clinical Oncology – Outcomes in Metastatic ZES

```